UPS: new member of the board of directors

UPS: new member of the board of directors

UPS  has announced that its board of directors has appointed Angela Hwang to the board, effective immediately.  

Hwang, age 54, is a member of Pfizer’s Executive Team and is Group President of the Pfizer Biopharmaceuticals Group, which comprises approximately 80% of Pfizer’s revenues. In this role, she leads more than 26,000 global colleagues and has responsibility for bringing over 600 innovative medicines and products to patients around the world.

“The UPS Board engaged in a thorough search and evaluation to find the right candidate for this role,” said UPS Executive Chairman of the Board David Abney. “Angela’s expertise in the healthcare sector will bring added talent to our Board as we oversee the company’s strategic growth efforts in this area.”

Hwang oversees seven commercial business units, which in 2019 generated nearly $40 billion in revenues, and impacted the lives of over 434 million patients across 125 countries. Together, these businesses strive to deliver transformational medicines that address major global health priorities in cancer, rare disease, inflammation & immunology, primary care, infectious diseases, and preventative care with vaccines.

“Angela is an outstanding, proven leader who brings added healthcare and global management experience to our Board,” said UPS Chief Executive Officer Carol Tomé. “We couldn’t be more thrilled to welcome Angela to the UPS Board of Directors during this time when UPS continues to expand its leadership in the healthcare logistics space, launching new healthcare services for UPS customers.”

Hwang is a 23-year veteran of Pfizer, and has held numerous leadership roles within the company. Prior to leading the Pfizer Biopharmaceuticals Group, she held more than 10 different positions in the company, spanning strategy, product development, marketing, sales, and general management. She is known as a transformational leader who drives for innovation and outstanding business performance and her experience covers a wide array of therapeutic areas and medicines in all lifecycle stages, as well as geographical breadth in both developed and emerging markets.

Relevant Directory Listings

Listing image

Doddle

Doddle powers PUDO networks and intelligent returns management for some of the world’s most innovative carriers and posts. Our experience building our own successful PUDO network in the UK means we have unprecedented insight into the needs of consumers, carriers and retailers meaning we can […]

Find out more

Other Directory Listings

Advertisement

Advertisement

Advertisement

P&P Poll

Loading

Which one of the following SCM technologies will you be investing in over the next 2-3 years?

Thank you for voting
You have already voted on this poll
Please select an option!





MER Magazine


The Mail & Express Review (MER) Magazine is our quarterly print publication. Packed with original content and thought-provoking features, MER is a must-read for those who want the inside track on the industry.

 

News Archive

Pin It on Pinterest

Share This